How can real-time analysis of the PD-L1 testing market boost precision medicine? | Diaceutics

How can real-time analysis of the PD-L1 testing market boost precision medicine?

March 13th, 2017

In an article for Clinical Lab Products magazine, The Evolution of the PD-L1 Testing Market, Peter Keeling and Ewelina Golebiewska examine how the extraordinarily dynamic PD-L1 space is providing opportunities to undertake real-time market analysis and ultimately improve our understanding of novel biomarker adoption.

This active approach to real-time analysis, combined with the insights of a dedicated prescriber panel established by Diaceutics to observe the situation, has generated predictions based on a hectic first few years of PD-L1 testing market development and an increasingly dynamic landscape.

Diaceutics believes that despite the uncertainties hanging over the first generation of diagnostic tests, PD-L1 will become a hyperconnected oncology biomarker. For instance, by the end of 2020, when the clinical utility of PD-L1 status will be proven, 75 per cent of all NSCLC trials for five PD-1/PD-L1 therapies are likely to require known PD-L1 status, bringing PD-L1 in line with ALK and EGFRm as key disease-based biomarkers. And yet, although it has been nearly 20 years since the launch of the first truly targeted cancer drug and companion biomarker—Herceptin and HER2—we are still suffering from the absence of attention to pre-launch market development for critical biomarkers.

Most of the issues that are detectable in the PD-L1 testing space have also been seen in previous biomarker programs. However, this is the first opportunity that analysts have found to conduct real-time scrutiny in order to track and understand the clinical and competitive impact of such tests as they come to market. The anti-PD-1 therapy class of drugs is slated to achieve $33 billion in annual revenues in 2022. But capturing much of this expected revenue will rely on appropriate application of PD-L1 testing—a field that remains significantly underdeveloped and underpowered to support all that is hoped for anti-PD-1 therapies.

Webinars & Podcasts

August 9th, 2018
Podcast: Oncology Patient Research
Why do we need to talk biomarkers with patients? Senior Director of Market Research at Diaceutics, Marianne Fillion, recently spearheaded an effort to gather insights directly from oncology patients to get an understanding of what they know about ...
April 20th, 2018
Podcast: PM Readiness Report 2018
Peter Keeling discusses the landscape and challenges for precision medicine, companion diagnostics, CDx or biomarker and conduit diagnostics are discussed including global laboratory test data analysis and forecasts for budget impact and value.
View all

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
September 11th, 2018
BRAF mutation testing in melanoma – Poster presented at European Congress of Pathology 2018
BRAF mutation testing in melanoma: a study including Austria, Germany and UK, highlighting concordance for current technologies, and potential requirement of more sensitive technologies in future applications.
View all publications
Facebook
Twitter
YouTube
LinkedIn